Zepbound stories

Sep 30, 2026

Eli Lilly's amylin-Zepbound combination shows record 23% weight loss in diabetes trial

Eli Lilly reported that its experimental combination of amylin drug eloraTZP with Zepbound (tirzepatide) achieved up to 23% weight loss in patients with type 2 diabetes and obesity, outperforming Zepbound alone and representing the highest weight loss seen in similar studies to date.

Sep 30, 20266 sources

Aug 12, 2026

Eli Lilly escalates legal fight against black market for experimental weight-loss drug retatrutide

Eli Lilly is stepping up legal action against a booming black market for retatrutide, an experimental weight-loss drug the company is counting on to expand its franchise beyond approved medications like Zepbound.

Aug 12, 20262 sources

Jul 14, 2026

Study finds frailty risks with GLP-1 drugs in older adults

A large study found potential signs of frailty in older adults taking Eli Lilly's Zepbound may signal relatively high risks for adverse outcomes, raising concerns about GLP-1 obesity drug use in elderly populations.

Jul 14, 20261 source

May 28, 2026

CVS Health Restores Coverage of Eli Lilly's Zepbound and Adds New Obesity Pill to Drug Plans

CVS Health announced it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option and begin coverage for the drugmaker's newly approved obesity pill, Forza.

May 28, 20262 sources

May 3, 2026

Eli Lilly Raises 2026 Guidance as GLP-1 Drug Demand Surges in Q1

Eli Lilly reported strong Q1 2026 financial results driven by massive growth in Mounjaro and Zepbound sales, leading the company to raise its full-year guidance amid surging demand for GLP-1 medications.

May 3, 20261 source

Top claims

▪Eli Lilly's EloraTZP combination approach targets three nutrient-stimulated hormone pathways—GLP-1, GIP, and amylin—to lightly engage multiple natural satiety systems rather than heavily targeting a single hormone system
▪EloraTZP combines eloralintide, an experimental selective amylin receptor agonist mimicking the pancreatic hormone amylin that signals fullness, with tirzepatide, the active ingredient in Eli Lilly's Zepbound and Mounjaro that targets GLP-1 and GIP gut hormones
▪Eli Lilly plans to initiate Phase 3 clinical trials for the EloraTZP combination treatment by the end of 2026, which will include adjusted dosing schedules to improve tolerability

Subtopics

Eli Lilly5 GLP-1 medications3 Lifestyle, Wellness and Nutrition3 Pharma3 Obesity treatment2 Pharmaceutical Industry2 Weight management2 Age related cognitive decline1 Clinical trials1 Corporate earnings1 Drug Approval and Clinical Trials1 Drug development1 Drug safety1 GLP-1 drugs1 Metabolic health1 Public healthcare1 Retatrutide1 US health policy & drug pricing1 Weight loss drugs1

Related timelines